EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient‐Derived Tumor Organoids Combined with Function‐Associated ScRNA‐Seq for Dissecting the Local Immune Response of Lung Cancer

Chang Liu, Kaiyi Li, Xizhao Sui, Tian Zhao, Ting Zhang, Zhongyao Chen, Hainan Wu, Chao Li, Hao Li, Fan Yang, Zhidong Liu, You-Yong Lu und 3 weitere

Advanced Science · 2024-08 · 11 (31)

DOI: 10.1002/advs.202400185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 19.06.2024. Verfasst von Chang Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, Tsinghua University, Beijing, 100084, China. Hauptthemen laut MEDLINE: Organoids, Lung Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Peking University People's Hospital Scientific Research Development Funds, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vitro models coupled with multimodal approaches are needed to dissect the dynamic response of local tumor immune microenvironment (TIME) to immunotherapy. Here the patient‐derived primary lung cancer organoids (pLCOs) are generated by isolating tumor cell clusters, including the infiltrated immune cells. A function‐associated single‐cell RNA sequencing (FascRNA‐seq) platform allowing both phenotypic evaluation and scRNA‐seq at single‐organoid level is developed to dissect the TIME of individual pLCOs. The analysis of 171 individual pLCOs derived from seven patients reveals that pLCOs retain the TIME heterogeneity in the parenchyma of parental tumor tissues, providing models with identical genetic background but various TIME. Linking the scRNA‐seq data of individual pLCOs with their responses to anti‐PD‐1 (αPD‐1) immune checkpoint blockade (ICB) allows to confirm the central role of CD8 + T cells in anti‐tumor immunity, to identify potential tumor‐reactive T cells with a set of 10 genes, and to unravel the factors regulating T cell activity, including CD99 gene. In summary, the study constructs a joint phenotypic and transcriptomic FascRNA‐seq platform to dissect the dynamic response of local TIME under ICB treatment, providing a promising approach to evaluate novel immunotherapies and to understand the underlying molecular mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsLung NeoplasmsTumor MicroenvironmentHumansImmunotherapyRNA-SeqSequence Analysis, RNASingle-Cell AnalysisCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsSingle-Cell Gene Expression Analysis

Stichwörter der Autor:innen

function‐associated single‐cell RNA sequencingimmune checkpoint blockadelocal tumor immune microenvironmentprimary lung cancer organoidtumor micro‐niche

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • School of Biomedical Engineering, Tsinghua University, Beijing, 100084, China.
  • Department of Thoracic Surgery, People's Hospital, Peking University, Beijing, 100034, China.
  • Beijing Advanced Innovation Centre for Biomedical Engineering, Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beiji…
  • Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101125, China.
  • Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), School of Oncology, Beijing Cancer Hospital and Institute, Peking University, Beijing, 100142, China.
  • Changping Laboratory, Beijing, 102299, China.

ORCID-Profile: Jun Wang, Peng Liu

Förderung

  • National Natural Science Foundation of China
  • Peking University People's Hospital Scientific Research Development Funds
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Liu, C., Li, K., Sui, X., Zhao, T., Zhang, T., Chen, Z., Wu, H., Li, C., Li, H., Yang, F., Liu, Z., Lu, Y. Y., Wang, J., Chen, X., & Liu, P. (2024). Patient‐Derived Tumor Organoids Combined with Function‐Associated ScRNA‐Seq for Dissecting the Local Immune Response of Lung Cancer. Advanced Science, 11(31). https://doi.org/10.1002/advs.202400185

Vancouver

Liu C, Li K, Sui X, Zhao T, Zhang T, Chen Z, et al. Patient‐Derived Tumor Organoids Combined with Function‐Associated ScRNA‐Seq for Dissecting the Local Immune Response of Lung Cancer. Advanced Science. 2024;11(31). doi:10.1002/advs.202400185

BibTeX
@article{Liu2024,
  author = {Liu, Chang and Li, Kaiyi and Sui, Xizhao and Zhao, Tian and Zhang, Ting and Chen, Zhongyao and Wu, Hainan and Li, Chao and Li, Hao and Yang, Fan and Liu, Zhidong and Lu, You-Yong and Wang, Jun and Chen, Xiaofang and Liu, Peng},
  title = {Patient‐Derived Tumor Organoids Combined with Function‐Associated ScRNA‐Seq for Dissecting the Local Immune Response of Lung Cancer},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {31},
  doi = {10.1002/advs.202400185}
}
Kostenlos starten →